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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Bisphosphonates (BPs) are used to treat osteoporosis and bonemetastases
frommalignancy. They may result in BPs-related osteonecrosis of the jaws (BRONJ) in a subset of
patients receiving BPs. This study examinedwhether conservative or aggressive surgical approach
could result in successful treatment of BRONJ lesions and assessed whether concomitant steroid
administration or tobacco smoking habit might hinder the remission of BRONJ lesions.
Methods: The 40 BRONJ patients were evenly divided into four different groups. Group 1 con-
tained 10 patients with concomitant corticosteroidmedication but without smoking habit. Group
2 contained 10 patients with smoking habit but without concomitant corticosteroid medication.
Groups 3 and 4 each consisted of 10 patients without concomitant corticosteroid medication
and smoking habit. To avoid bias, each group contained equal number of patients with different
stages of BRONJ. Patients in Groups 1, 2, and 3 received conservative treatment, including anti-
biotic coverage, antibacterial solution irrigation, and minor surgical debridement. Patients in
Group 4 were treated with aggressive surgical excision of necrotic bone segment.
Results: The mean duration to achieve complete remission of BRONJ lesion was 19.7  0.6,
18.2 0.5, 13.0 1.0, and 7.6 1.1 months for patients in Groups 1, 2, 3 and 4, respectively.
Student’s t-test showed significant differences in the mean duration to achieve complete remis-
sion of BRONJ lesion between Groups 1 and 3, between Groups 2 and 3, between Groups 3 and 4,
between Groups 1 and 4, and between Groups 2 and 4 (all p values < 0.001).
Conclusion: Although both conservative and aggressive surgical approaches can result in success-
ful treatment of BRONJ lesions, aggressive surgical treatment needs a shorter mean duration tohave no conflicts of interest relevant to this article.
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Treatment outcomes for 40 osteonecrosis patients 167achieve complete remission of BRONJ lesion than conservative treatment. Concomitant cortico-
steroid administration or tobacco smoking may prolong the duration for complete remission of
BRONJ lesion.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Bisphosphonates (BPs) act as osteoclast inhibitors that are
administered by either oral or intravenous route. Oral BPs
such as alendronate and risedronate are used primarily to
manage osteoporosis or Paget disease. Intravenous BPs such
as zoledronate and pamidronate are used mainly to treat
hypercalcemia of malignancy, osteolytic bone metastases,
or osteolytic lesions of multiple myeloma.1e3 Despite these
benefits, they may result in BPs-related osteonecrosis of
the jaws (BRONJ) in a subset of patients receiving these
drugs. BRONJ lesions may occur spontaneously or after
simple dentoalveolar surgery.1e3 The pathogenesis for
BRONJ is still unclear, but appears to be related to the
profound inhibition of osteoclast function and bone
remodeling by BPs, a possible direct cytotoxic effect of BPs
on osteocytes, and antiangiogenic properties of BPs.4
The BRONJ was first described by Marx et al in 2003.5
Woo et al6 reviewed 368 BRONJ lesions published before
January 31, 2006 and found that the prevalence of osteo-
necrosis in cancer patients receiving intravenous BPs is 6%e
10%. Cumulative data indicate that the prevalence of
BRONJ in cancer patients ranges from 1% to 12%7e9 and that
in patients taking oral BP for osteoporosis varies from 0.01%
to 4%.10e12 Several potential risk factors are identified to be
associated with the development of BRONJ. These include
tobacco smoking habit,13e15 concomitant corticosteroid
medication,7,13,15 kind, route (oral or intravenous) and
duration of BP administration,1e3 treated diseases of the
patients (such as osteoporosis, metastatic breast or pros-
tate cancer, multiple myeloma),7,9,12e18 and precipitating
events (including tooth extraction, dental implant place-
ment, periodontal or apical surgery).7,9,16,18 In general,
BRONJ lesion seems to be time- and dose-dependent
because of the long half-life of BPs.6 Moreover, the more
potent intravenous BPs (such as zoledronate) are signifi-
cantly stronger risk factors for BRONJ than the oral BPs.13
There are still no standard treatment regimens for
different stages of BRONJ lesions. It is also not clear
whether the aggressive approach is better than the
conservative approach for treatment of BRONJ. In addition,
we did not know whether risk factors such as concomitant
corticosteroid administration or tobacco smoking habit
might impede the remission of BRONJ lesions. In this study,
the demographic and clinical data of 40 BRONJ patients
were collected and analyzed. The characteristic clinical
features of the patients were described. These 40 patients
were evenly divided into four groups to assess whether
concomitant corticosteroid administration or tobacco
smoking habit might hinder the remission of BRONJ lesions
and further to examine whether conservative or aggressive
surgical approach could result in successful treatment of
BRONJ lesions. We hope to validate and establish
a successful protocol for treatment of BRONJ lesions inorder to enhance masticatory ability and to improve the
quality of life of BRONJ patients.
Materials and methods
The study group consisted of 40 BRONJ patients (16 men
and 24 women, age range 52e95 years, mean 69 11
years). All the patients were seen consecutively, diag-
nosed, and treated in the Department of Dentistry, Taipei
City Hospital, Renai branch, Taipei, Taiwan from 2006 to
2011. The patient inclusion criteria included those with (1)
current or previous treatment with a BP, (2) exposed and
necrotic bone in the maxillofacial region that has persisted
for more than 8 weeks, and (3) no history of radiotherapy to
the jaws, which were defined by American Association of
Oral and Maxillofacial Surgeons.2 The demographic and
clinical data including patient age and sex, lesion location,
tobacco smoking habit, corticosteroid medication, kind
(alendronate, zoledronate, or both alendronate and
zoledronate), route (oral or intravenous), and duration of
BP administration, treated diseases of the patients (such as
osteoporosis, metastatic breast or prostate cancer, and
multiple myeloma), precipitating events (such as sponta-
neous, tooth extraction or denture wearing), and stages of
BRONJ were recorded (Table 1). The stages of BRONJ were
defined based on the criteria previously described by Rug-
giero et al.1,2 In brief, Stage 1 BRONJ showed exposed and
necrotic bone that is asymptomatic, Stage 2 BRONJ exposed
and necrotic bone associated with infection as evidenced
by pain and erythema with or without purulent drainage,
and Stage 3 BRONJ exposed and necrotic bone in patients
with pain, infection, and one or more of the following:
pathologic fracture, extraoral fistula, oral antral/oral nasal
communication, or osteolysis extending to the inferior
border or the sinus floor.
The 40 BRONJ patients were evenly divided into 4
different groups. Group 1 contained 10 patients with
concomitant corticosteroid medication but without
smoking habit. Group 2 contained 10 patients with smoking
habit but without concomitant corticosteroid medication.
Groups 3 and 4 each consisted of 10 patients without
concomitant corticosteroid medication and smoking habit.
Each group contained equal number of patients with
different stages of BRONJ lesions (Stage 1, one patient;
Stage 2, seven patients; and Stage 3, two patients).
Patients in Groups 1, 2, and 3 received conservative
treatment, including antibiotic coverage (augmentin 1 g or
Unasyn 375 mg, one tablet twice per day) for 2e4 weeks,
antibacterial solution irrigation daily by the patient or the
patient’s family member, and minor surgical debridement
when needed. During each irrigation procedure, the BRONJ
lesion was irrigated by 30 cc of 0.1% chlorhexidine solution
for 5e7 times with the total amount of solution being
200 cc. Minor surgical debridement was performed by the
Table 1 Demographic and clinical features of the 40 BRONJ patients.
Clinical variables Treated diseases
Osteoporosis
(nZ 19)
Metastatic breast
cancer (nZ 12)
Metastatic prostate
cancer (nZ 5)
Multiple
myeloma (nZ 4)
Age
> 80 y 6 0 1 1
60e80 y 11 2 3 3
< 60 y 2 10 1 0
Sex
Men 8 0 5 3
Women 11 12 0 1
Location
Mandible only 12 8 5 2
Maxilla only 7 4 0 2
Corticosteroid medication
With 5 2 3 0
Without 14 10 2 4
Tobacco smoking
With 8 0 1 1
Without 0 0 0 0
Bisphosphonate used
Alendronate (oral) 19 0 0 0
Zoledronate (intravenous) 0 10 5 4
Combinations 0 2 0 0
*Induction period for BRONJ lesion
< 1 y 0 3 2 2
1e2 y 4 2 3 0
2e3 y 4 3 0 2
> 3 y 11 4 0 0
Precipitating events
Spontaneous 1 4 0 1
Tooth extraction 18 5 4 3
Denture trauma 0 3 1 0
Stage of BRONJ
Ⅰ 3 0 1 0
II 14 8 2 4
Ⅲ 2 4 2 0
*Chi-square test found that patients treated with zoledronate alone or with both zoledronate and alendronate needed a significantly
shorter period to develop a BRONJ lesion than patients treated with alendronate alone (pZ 0.020).
BRONJZ bisphosphonates-related osteonecrosis of the jaws.
168 L.-W. Lee et al.dentist after irrigation, in which the necrotic bone frag-
ments were removed by cotton pliers if they were sepa-
rated from the adjacent bone or by a high speed handpiece
with a diamond bur if they attached to the adjacent bone.
After that, the sharp bone edge was rounded by a bone file
or a rongeur. The patients were followed up twice per week
in the first month and then once per week thereafter. The
patients were also recommended to keep good oral hygiene
by oral rinse with 0.1% chlorhexidine solution after each
meal.Patients in Group 4 were treated with aggressive surgical
intervention in the operation room under general anes-
thesia. Usually, a large necrotic bone segment was removed
by an ultrasonic bone saw. A bone file or rongeur was used
for rounding the sharp bone edge. Then, the bone defect
was closed by sutures. If the bone defect could not be
closed by sutures, COE pack (GC America, Alsip, IL, USA)
was used to cover the open wound. Antibiotics were
prescribed to the patient for at least 2 weeks after surgery.
The patients were seen once per week in the first two
Treatment outcomes for 40 osteonecrosis patients 169months and then followed up once per month thereafter.
The resected bone segment was sent for histopathological
examination and diagnosis.
The mean durations to achieve complete remission of
BRONJ lesion were compared first among four groups by
analysis of variance (ANOVA) and then between any two
groups by Student’s t-test. The induction periods for clin-
ical bone exposure and symptoms were compared between
patients receiving alendronate alone and patients receiving
zoledronate alone or both zoledronate and alendronate by
chi-square test.
Results
Demographic and clinical features of the 40 BRONJ patients
are shown in Table 1. Nineteen patients were treated for
osteoporosis, 12 for metastatic breast cancer, five for
metastatic prostate cancer, and four for multiple myeloma.
Twenty-seven (67.5%) bone exposures occurred in the
mandible only and 13 (32.5%) in the maxilla only. Ten
patients had concomitant corticosteroid administration and
another 10 patients had concurrent tobacco smoking habit.
Of the 40 patients, 19 received alendronate alone, 19
received zoledronate alone, and two received both
alendronate and zoledronate. The mean induction period
for clinical bone exposure and symptoms was 5 (range
1e11) years for those receiving alendronate alone, 3 (range
0.5e6) years for those receiving zoledronate alone, and 4
(range 3e5) years for those receiving both alendronate and
zoledronate. Chi-square test found that patients treated
with zoledronate alone or with both zoledronate and
alendronate needed a significantly shorter period to
develop a BRONJ lesion than patients treated with alendr-
onate alone (pZ 0.020). The precipitating events that
produced the bone exposures were spontaneous in 6 cases
(15%), tooth extraction in 30 cases (75%), and denture
trauma in four cases (10%). By the definition described
before in the materials and methods section, Stage 1 BRONJ
lesion was found in four patients, Stage 2 in 28 patients,
and Stage 3 in eight patients (Table 1).
Our 40 BRONJ patients were evenly divided into four
groups and treated by either conservative or aggressive
approach. The endpoint of this study was completeTable 2 Mean durations to achieve complete remission of BRO
Group Regimen of treatment Corticosteroid
medication
Tobacco
smoking
1 (nZ 10) Conservative treatmenta With Without
2 (nZ 10) Conservative treatmenta Without With
3 (nZ 10) Conservative treatmentb Without Without
4 (nZ 10) Aggressive treatmentb Without Without
There was a significant difference in the mean duration to achieve com
variance (p< 0.001). Further comparisons by Student’s t-test showed
remission of BRONJ lesion between groups 1 and 3, between groups
between groups 2 and 4 (all p values < 0.001).
BRONJZ bisphosphonates-related osteonecrosis of the jaws.
a Conservative treatment included antibiotic coverage, antibacteria
b Aggressive treatment included radical surgical excision of the necremission of BRONJ lesion, i.e., no exposed bone, pain,
infection or fistula and radiographic evidence showing
a significant improvement of bone healing. The mean
duration to achieve complete remission of BRONJ lesion
was 19.7 0.6 (range 19e21) months, 18.2 0.5 (range
17.5e19) months, 13.0 1.0 (range 12e15) months, and
7.6 1.1 (range 5.5e8.5) months for patients in Groups 1,
2, 3 and 4, respectively (Table 2). There was a significant
difference in the mean duration to achieve complete
remission of BRONJ lesion among four groups by ANOVA
(p< 0.001). Further comparisons by Student’s t-test
showed significant differences in the mean duration to
achieve complete remission of BRONJ lesion between
Groups 1 and 3, between Groups 2 and 3, between Groups 3
and 4, between Groups 1 and 4, and between Groups 2 and
4 (all p values < 0.001). These results indicate that
conservative treatment with antibiotic administration,
antibacterial solution irrigation and minor surgical
debridement needed longer mean duration to achieve
complete remission of BRONJ lesion (Fig. 1 AeD) than
aggressive surgical treatment (Fig. 2 AeD). In addition,
patients with either concomitant corticosteroid medication
or tobacco smoking habit took a longer mean duration to
achieve complete remission of BRONJ lesion than those
without both concomitant corticosteroid medication and
tobacco smoking habit.
Histopathologically, the necrotic bone fragment showed
empty lacunae and bacterial clumps in the bone marrow
spaces. No osteoclasts nor were any osteoblasts were found
around the necrotic bone trabeculae. In some cases, colo-
nies of actinomycotic organisms surrounded by a collection
of polymorphonuclear leukocytes are found in the bone
marrow spaces.
Discussion
To avoid bias, our 40 BRONJ patients were evenly divided
into four groups, with each group having equal number of
patients with different stages of BRONJ lesions. We found
that patients receiving conservative treatment, with
concomitant corticosteroid medication, or with smoking
habit needed longer mean duration to achieve complete
remission of BRONJ lesion than those receiving aggressiveNJ lesions in patients in four different groups.
Route of
bisphosphonate
administration
Stage of
BRONJ
Duration to achieve
complete remission of
the lesion (mo)
Oral/5 Intravenous/5 I/1 patient
II/7 patients
III/2 patients
19.7 0.6
Oral/8 Intravenous/2 18.2 0.5
Oral/3 Intravenous/7 13.0 1.0
Oral/3 Intravenous/7 7.6 1.1
plete remission of BRONJ lesion among four groups by analysis of
significant differences in the mean duration to achieve complete
2 and 3, between groups 3 and 4, between groups 1 and 4, and
l solution irrigation, and minor surgical debridement.
rotic bone segment and antibiotic coverage.
Figure 1 Initial and follow-up photographs of a 92-year-old female osteoporosis patient with stage III BRONJ lesion. (A) Initial
clinical photograph showing a skin sinus tract at the submental area; (B) initial radiograph exhibiting a large radiolucent and
radiopaque lesion in the middle and left part of the mandible; (C) follow-up clinical photograph demonstrating healing of the skin
sinus tract after 12-month conservative treatment; (D) follow-up radiograph revealing a significant improvement of bone healing
after 12-month conservative treatment although there is still a residual radiolucent and radiopaque lesion left. BRONJZ bi-
sphosphonates-related osteonecrosis of the jaws.
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medication, or without smoking habit, respectively. These
results indicate that aggressive surgical treatment may be
better than conservative treatment to achieve complete
remission of BRONJ lesion. In addition, concomitant corti-
costeroid medication or tobacco smoking may inhibit the
bone healing process for BRONJ patients.
In this study, 10 patients took corticosteroid because of
underlying autoimmune diseases such as systemic lupus
erythematosus, rheumatoid arthritis or Sjo¨gren syndrome.
We found that patients with concomitant corticosteroid
administration took a longer mean duration to achieve
complete remission of BRONJ lesion than those without
concomitant corticosteroid administration. This finding was
consistent with the results reported by other investiga-
tors,7,13,15 in which they suggested that concurrent cortico-
steroid use along with a BP may cause the osteonecrosis to
occur sooner, to bemore severe, and to responsemore slowly
to the treatment. However, Woo et al6 and Lazarovici et al19
reported no significant association of concomitant cortico-
steroidusewith theoccurrenceandhealing of BRONJ lesions.
Glucocorticoids suppress the inflammatory response by
inhibiting synthesis of the two main inflammatory products,
prostaglandinsand leukotrienes. Glucocorticoids can inhibit
prostaglandin synthesis at the level of both phospholipase
A2and cyclooxygenaseisomerase.20 Furthermore, glucocor-
ticoids are able to prevent the transcription of pro-
inflammatorygenes, including interleukins(IL) 1B, IL-4, IL-5,
and IL-8, chemokines, cytokines, granulocyte-macrophage
colony-stimulating factor, and tumor necrosis factor-a genes.21 Glucocorticoids also suppress the cell-mediated
immunity. They act by inhibiting genes that code for the
cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8and interferon-
g, themost important ofwhich is IL-2,which is a potent T-cell
growth factor. Smaller cytokineproduction in turn reduces
the T-cellproliferation.22 Because corticosteroids have both
anti-inflammatory and anti-immune effects, concomitant
administration of corticosteroids may result in an increased
susceptibility to microorganism infection in BRONJ lesions
and a delayed bone healing. Moreover, long-term cortico-
steroid medication may induce osteoporosis.23 Triamcino-
lone acetonide can inhibit cell proliferation and collagen
synthesis as well as can increase collagen degradation in
normal skin fibroblasts.24 Corticosteroid-induced osteopo-
rosis, inhibition of fibroblast growth and collagen synthesis,
andaugmentation of collagendegradationmayfinally lead to
prolonged bone healing of BRONJ lesions.
Our study found that patients with tobacco smoking
habit needed a longer mean duration to achieve complete
remission of BRONJ lesion than those without tobacco
smoking habit. The similar results were also reported by
other investigators.13e15 It has been reported that smokers
tend to have deeper periodontal pockets, more alveolar
bone loss, more severe destructive periodontal disease,
and fewer teeth in the oral cavity than non-smokers.25,26
Furthermore, there is good evidence that smoking can
depress the activity of oral polymorphonuclear leukocytes
and in turn reduce their chemotactic response, mobility,
and phagocytic ability. In addition, smoking can reduce
gingival blood flow and crevicular fluid output, resulting in
Figure 2 Initial and follow-up photographs of a 58-year-old female breast cancer patient with stage III BRONJ lesion. (A) Initial
clinical photograph showing a large exposed necrotic bone fragment at the anterior and right maxilla; (B) initial radiograph
exhibiting a radiolucent and radiopaque lesion in the anterior and right maxilla; (C) follow-up clinical photograph revealing healing
of the anterior and right maxillary lesion with intact alveolar mucosa 8.5 months after radical surgical removal of the necrotic bone
fragment; (D) follow-up radiograph revealing healing of the anterior and right maxillary bone lesion 8.5 months after radical
surgical removal of the necrotic bone fragment. BRONJZ bisphosphonates-related osteonecrosis of the jaws.
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the region of gingival crevice.25,26 Nicotine may increase
vasoconstriction in bone, leading to an ischemic state that
is prone to cause osteonecrosis.27 Nicotine can disturb the
attachment of human fibroblasts to glass and human root
surfaces.28 Nicotine can also inhibit proliferation, attach-
ment, alkaline phosphatase production, and chemotaxis of
periodontal ligament fibroblasts.29 Nicotine inhibits
collagen synthesis and alkaline phosphatase activity of
osteoblast-like cells isolated from chick embryo calvar-
iae.30 Nicotine also impairs bone healing in a rat animal
model.31 Moreover, nicotine suppresses cellular prolifera-
tion and stimulates alkaline phosphatase activity in UMR
106-01 osteoblast-like cells, suggesting that the use of
tobacco is associated with the development of osteoporosis
and alveolar bone loss.32 The above-mentioned findings
indicate that smoking can reduce the human cellular and
humoral immunity and further impairs periodontal wound
healing and alveolar or jaw bone healing.
Our results suggest that for BRONJ lesions aggressive
surgical treatment can obtain a prompter bone healing than
conservative treatment. In case of radical resection of
a diseased bone segment, both necrotic bone tissue and
infectious source of microorganisms are removed. This may
result in a quick and undisturbed bone healing if the
surgical wound is well cared. In contrast, conservative
treatment removes the sequestra piece by piece. Usually
there are residual necrotic bone tissue and infectiousmicroorganisms left in the BRONJ lesion. Therefore, it
needs multiple procedures and a longer duration to achieve
complete remission of BRONJ lesion.
Clinical survey of this study revealed that patients
receiving intravenous BP (zoledronate) would develop
BRONJ lesions in a shorter duration than patients receiving
oral BP (alendronate). The similar result was also reported
by others.2,9,13,33 This study and previous studies also found
that BRONJ lesions tend to occur in elder patients than in
younger patients.7,16 Of the 40 BRONJ lesions, 67.5%
occurred in patients older than 60 years of age or in the
mandible and 32.5% in patients younger than 60 years of
age or in the maxilla. The mandible to maxilla ratio for
BRONL lesions was 2.1:1. Moreover, in 75% of our patients
the BRONJ lesions were induced by tooth extraction. Woo
et al6 did a systematic review of 368 BRONJ lesions pub-
lished before January 31, 2006. They found that the
mandible is more commonly affected than the maxilla (2:1
ratio), and 60% of cases are preceded by a dental surgical
procedure. A higher frequency for occurrence of BRONJ in
the mandible than in the maxilla has also been reported by
others.2,7,9,16,18 In addition, this and other investigations
also demonstrated that invasive dental procedures such as
tooth extraction, periodontal surgery, and periapical
surgery are the more common triggering events for BRONJ
lesions.2,7,9,16,18 The aforementioned findings indicate that
all sites of potential jaw infection should be eliminated
before BP therapy is initiated in these patients to reduce
172 L.-W. Lee et al.the necessity of subsequent dentoalveolar surgery and in
turn to lower the risk for contracting BRONJ.
In conclusion, this study found that BRONJ patients with
concomitant corticosteroid medication or with smoking
habit were more difficult to treat than those without
concomitant corticosteroid medication or without smoking
habit, respectively. Although both conservative and
aggressive surgical approaches can result in successful
treatment of BRONJ lesions, aggressive surgical treatment
may need a shorter mean duration to achieve complete
remission of BRONJ lesion than conservative treatment.
Concomitant corticosteroid administration or tobacco
smoking habit may prolong the duration for complete
remission of BRONJ lesion.References
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